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Objectives. Review of public health perspectives of preeclampsia in developing countries and implications for health system
strengthening. Methods. Literature from Pubmed (MEDLINE), AJOL, Google Scholar, and Cochrane database were reviewed.
Results. The prevalence of preeclampsia in developing countries ranges from 1.8% to 16.7%. Many challenges exist in the
prediction, prevention, and management of preeclampsia. Promising prophylactic measures like low-dose aspirin and calcium
supplementation need further evidence before recommendation for use in developing countries. Treatment remains prenatal care,
timely diagnosis, proper management, and timely delivery. Prevailing household, community, and health system factors limiting
eﬀective control of preeclampsia in these countries were identiﬁed, and strategies to strengthen health systems were highlighted.
Conclusion. Overcoming the prevailing challenges in the control of preeclampsia in developing countries hinges on the ability of
health care systems to identify and manage women at high risk.
1.Introduction
Preeclampsia is a pregnancy-related hypertensive disorder
occurringusuallyafter20weeksofgestation.Ifleftuntreated,
it progresses to eclampsia [1]. Preeclampsia and eclampsia
are not distinct disorders but the manifestation of the
spectrum of clinical symptoms of the same condition. The
mildest disorder in this continuum is pregnancy-induced
hypertension. Inpreeclampsia, hypertensionand proteinuria
are present, and when convulsions occur in addition to these
signs, the condition is referred to as eclampsia [2].
Preeclampsia has remained a signiﬁcant public health
threat in both developed and developing countries con-
tributing to maternal and perinatal morbidity and mortality
globally [3–6]. However, the impact of the disease is felt
more severely in developing countries [7, 8], where, unlike
other more prevalent causes of maternal mortality (such as
haemorrhage and sepsis), medical interventions may beinef-
fective due to late presentation of cases [9–11]. The problem
is confounded by the continued mystery of the aetiology and
the unpredictable nature of the disease [12]. Thus, the aim
of this paper is to highlight the challenges militating against




Literature providing evidence on the diagnosis, preven-
tion, treatment, and overcoming challenges to the control
of preeclampsia published between 2000 and 2010 were
reviewed. Search termsincluded“preeclampsia”, “eclampsia”,
“developing countries”, and “control”. These literatures were
accessed from Pubmed (MEDLINE), AJOL, Google Scholar,
and Cochrane Database of Systematic Reviews. Searches
werealsosupplementedwithrecommendationsfromoutside
experts and reviews of bibliographies of other relevant
articles and systematic reviews.2 Journal of Pregnancy
3.Results
3.1. Burden of Preeclampsia. Worldwide, the incidence of
preeclampsia ranges between 2% and 10% of pregnancies.
The incidence of preeclampsia, the precursor to eclampsia,
varies greatly worldwide. WHO estimates the incidence
of preeclampsia to be seven times higher in developing
countries (2.8% of live births) than in developed countries
(0.4%) [13]. The incidence of eclampsia in the developed
countries of North America and Europe is similar and
estimated to be about 5–7 cases per 10,000 deliveries. On
the other hand, incidence of eclampsia in developingnations
varies widely, ranging from 1 case per 100 pregnancies to
1 case per 1700 pregnancies [2, 14]. Rates from African
countriessuchasSouthAfrica,Egypt,Tanzania, andEthiopia
vary from 1.8% to 7.1% [15–18]. In Nigeria, prevalence
ranges between 2% to 16.7% [19–21].
3.2. Public Health Perspectives of Preeclampsia
3.2.1. Challenges in Detection and Prevention of Preeclampsia.
Prevention of any disease process requires the availability of
methods for prediction of those at high risk for the disorder.
Although numerous clinical and biochemical tests have been
proposed for prediction or early detection of preeclampsia,
most remain unrealistic for general use in most developing
countries. At present, there is not a single reliable and
cost-eﬀective screening test for preeclampsia which can be
recommended for use in most developing countries [22].
Althoughsome studiesonuterineartery Dopplerstudiesand
ﬁrst-trimester maternal serum markers for early detection
of preeclampsia have shown promise [23–25]. There is not
enough evidence to suggest their routine use in clinical
practice, more so in resource poor settings [26].
In terms of prophylaxis, aspirin therapy has been shown
to be beneﬁcial in decreasing the occurrence of preeclampsia
in speciﬁc populations, for example, those with abnormal
second trimester uterine Doppler ﬂow [27–30]. However,
to recommend its widespread use in all patients is not
judicious or evidence based. In the same vein, even though
the Cochrane review has stated some beneﬁt in calcium
supplementation, particularly for those at greatest risk
and those with low baseline calcium intake [31, 32], the
problemofselecting appropriatepatientstobe started on the
therapycanbeburdensome froma publichealth perspective.
Similarly, ﬁndings of earlier studies which had indicated
the beneﬁts of vitamin supplementation [33–39] have been
refuted by a recent study by the WHO particularly for
vitamins C and E [40].
3.2.2. Challenges in the Management of Preeclampsia. It
is evident that to tackle preeclampsia eﬀectively in any
population, functional health systems are imperative and so
is access to health care. However, in the vast majority of
developingcountriesparticularly in Africa, healthcare access
is limited due to a number of factors resulting in three levels
of delay.
Delay in the Decision to Seek Care. Delayed responses at
the household level to obstetric emergencies often arise as a
result of inadequate information on when to seek help and
sometimes on where to seek help [41–43]. This is worsened
by lack of decision-making power, poverty, and the rising
cost of health care [44, 45]. The consideration of user fees
and the resultant catastrophic expenditure often result in
fatal delays in care seeking [46]. Some sociodemographic
(e.g., level of education and marital status) and cultural
underpinnings of maternal health-seeking behaviour have
also been documented [47].
Delay in Reaching the Health Facility. Lack of access to
qualitycare has been said to bethe main obstacleto reducing
maternal mortality in low-income countries [46]. These are
due to the location, distance, and lack of transport to health
facilities. In Nigeria, for example, up to 50% of rural women
livemorethan5kmfromthenearesthospital,andmanyhave
no way to get to health facilities except by walking—even
when in labour [48]. The inequitable distribution of health
f a c i l i t i e sw h i c hi si nf a v o u ro fu r b a nc o m m u n i t i e si sa l s o
contributory [21]. Furthermore, the referral delays arising
fromthetrajectory ofvisitstootherorthodoxand alternative
medical practitioners have been documented to account for
46.4% of all cases of eclampsia [49, 50].
Delays in Health Service Provision. Delays which arise in
health facilities have also been shown to prevent women
from receiving the care they need before, during, and after
childbirth. For instance, in many countries where the health
insurance scheme is still in the teething stage, getting care in
emergencies may be impossible for the poor or insured [51].
The attitudes of health service providers and perceived poor
qualityofcarearealsoidentiﬁedbarriers[4,52].Thisismade
worse by the lackof trained personnel and lack ofequipment
and supplies [45]. For instance, even though the eﬃcacy
of magnesium sulphate has been documented by several
researchers [21, 53], studies have shown that magnesium
sulphate was not routinely administered [41, 54], and use is
often limited to teaching hospitals [55]. Lack of availability
of the drug and appropriate health personnel required for
its administration as well as cost were the frequently raised
obstacles [56].
3.2.3.HealthPolicies. Atmacro- and microhealthsystem lev-
els, there are deﬁcient policy guidelinesand implementation.
This has been blamed on poor data for decision making
[56]. For example, reliable statistics about women dying
due to eclampsia are diﬃcult to obtain because of the poor
quality of vital statistics registration systems and hospital
records in many developing countries [57]. In addition, a
sizable number of deliveries take place at home, and thus,
there are no records at all for these births or their sequelae
[56]. In addition, health policy development is usually not
evidence based. This is because policy makers are often
poorly informed of, and insuﬃciently involved in the use of
research in policy development [58].Journal of Pregnancy 3
3.3. Recommendations
3.3.1. Risk Assessment and Clinical Management. The WHO
focused antenatal care strategy recommends screening for
preeclampsia during the third antenatal visit at 32 weeks
[59]. In developing countries, strategies for risk assessment
should still be based on obstetric and medical history and
clinical examination of women. Pregnant women should
be assessed at their ﬁrst antenatal clinic for risk factors of
preeclampsia such as young age, nulliparity, ﬁrst pregnancy
after age of 35 years, obesity prior to the current pregnancy,
multiple gestation, prior history of preeclampsia, diabetes
mellitus, and hypertension [1, 60–62]. It is, however, impor-
tant to note that the presence of these factors is not a surety
todevelopingpreeclampsia. Ithasbeen shown that screening
for preeclampsia using maternal history was accurate in only
45.3% of cases [63].
Routine screening for preeclampsia based on measure-
ment of blood pressure among all pregnant women should
be practised as recommended by the World Health Orga-
nization [64, 65]. Where resources are available it is best to
measure blood pressure using a mercury sphygmomanome-
ter [66]. Urinalysis for protein should also be routinely done
at every antenatal visit for pregnant women in developing
countries as a complement to routine blood pressure mea-
surement.Thediagnosticcriteriaforpreeclampsiadeveloped
by the National Blood Pressure Education Program Working
Group which are still traditionally used in clinical practice
are systolic blood pressure of 140mmHg or higher or a
diastolic blood pressure of 90mmHg or higher on at least
two occasions at least 4–6 hours apart occurring after 20
weeks of gestation in a woman whose blood pressure had
previously been normal. In addition to this, the presence of
proteinuria with excretionof0.3gormore ofproteinina24-
hour urine specimen or 1+ or greater on two random urine
samples collected four or more hours apart [67, 68].
Once recognised, depending on the severity, options of
care include continued foetal and maternal evaluation, anti-
hypertensive therapy, and timely delivery (the only deﬁnitive
cure). There is signiﬁcant evidence which supports the use
of magnesium sulphate to prevent seizures in women with
severe preeclampsia and eclampsia [1, 67, 69]. Magnesium
sulphate has been compared with diazepam [70], phenytoin
[71], and lytic cocktail [72] in randomized trials and results
revealed that it produced a greater reduction in the risk of
maternal death and recurrence of convulsions than other
agents [73].
Furthermore, a continuum of care must be ensured. For
women to beneﬁt from the existing cost-eﬀective interven-
tions,theymusthaveantenatalcareinpregnancy,skilledcare
during delivery and postnatal care [74]. While antenatal care
and skilled delivery could prevent seizures, postnatal visits
are important to assess the recovery of the woman and to
discuss what might happen in the future.
3.3.2. Society and Community Interventions. Social factors
have been recognised as inﬂuencing up to 27% of maternal
deaths [75]. So, raising awareness of the need for women
to reach emergency care without delay if complications arise
during delivery is particularly critical. This is to ensure quick
and eﬀectivemedical intervention and to increase the chance
of therapeutic success [1, 44]. Since many women deliver
alone or with a relative [48], community members must
also be trained to recognize danger signs and develop plans
for emergencies, including transport to hospitals or health
centre. Prompt health seeking behaviour is essential because
reduction of the risk of death becomes more diﬃcult when
complications have developed [44].
3.3.3. Health System Strengthening. The majority of intra-
partum maternal deaths have been shown to occur in poorly
performing health systems [76]. The evidence provided by
some developing countries who have shown remarkable
reduction in maternal mortality [75, 77, 78]s h o w st h a t
maternal safety must be made a priority health issue by
the government and health workers. An increased focus on
qualityandaccountabilityisalsoneededtosecurethetrust of
consumers [79]. Political commitment to mobilize necessary
resources to the health sector to improve the quality of
emergency obstetric service must be shown by ensuring the
availability of trained personnel, drugs, and equipment at
every level of care. Referral services to emergency obstetric
care must be prompt and aﬀordable to limit delays when
skills or facilities are lacking [80]. Improvements in service
deliverycanbeachievedthroughtheuseofcasemanagement
protocols for obstetric emergencies at each level of care and
by monitoring standards of practice. Magnesium sulphate
should be part of every developing country’s list of essential
drugs and national protocols on magnesium sulphate as
the preferred treatment for preeclampsia and eclampsia
should be developedand/orreinforced. To improvematernal
health, barriers to accessing health services must be iden-
tiﬁed and addressed at all levels, with intensiﬁed eﬀorts at
community mobilization and engagement [81]. The use of
data to improve quality of care is also important especially
improving reporting systems andrecord-keepingpracticesto
estimate disease burden to aid service planning and delivery
[78]. Maternal death audits would aid the understanding of
the pathways tosurvival and death and help in local eﬀortsat
improvement. It would also aid in identifying substandard
care and avoidable factors in eclampsia-related maternal
deaths [56, 82].
4.Conclusions
With the target of the Millennium Development Goals in
sight, preeclampsia/eclampsia needs to be identiﬁed as a
priority area in reducing maternal mortality in developing
countries. Since the mainstay of control remains health
care based strategies, national governments and supporting
agencies should channel eﬀorts at strengthening the public
health systems and improving access to trained health care
providers. Further research is needed to understand the
causes and the best preventive strategies for preeclampsia
speciﬁc to geographic areas. However, based on current
data, better access to appropriate obstetric care, particularly4 Journal of Pregnancy
during labour and delivery and better screening and treat-
ment of identiﬁed cases should reduce preeclampsia rates in
developing countries.
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